title: A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome.
abstract: A prospective randomized trial was conducted to compare the effect of diltiazem (DILT) with ketoconazole (KETO) on sparing of cyclosporine dose and renal transplant outcome. Renal allograft recipients 18 years old and older were eligible for the study. Triple immunosuppression (TRIPLE) including prednisone, azathioprine, and CsA was administered to all patients. The maintenance CsA dose varied by study group. Patients were randomized to receive one of three treatment strategies: group 1-TRIPLE (CsA 8 mg/kg/day); group 2--TRIPLE (CsA 6 mg/kg/day) + DILT (60 mg b.i.d.); group 3--TRIPLE (CsA 3 mg/kg/day) + KETO (200 mg/day). Modification of the DILT dose was allowed as needed to effect blood pressure control in group 2 patients. Mean 1-month CsA dose reductions were 30% and 60% of controls in group 2 and 3, respectively. A continued effect over time was observed in patients administered KETO but not DILT. At 1 year patients taking KETO required an average of 77% less CsA than the average dose necessary to effect similar parent CsA blood levels when no enzyme inhibitor was used. The use of KETO and DILT for 1 year allowed for 53% and 14% reductions in CsA cost, respectively. These savings include the cost of the KETO or DILT. Serum creatinines, mean arterial pressure (MAP), and incidence of liver function abnormalities were similar throughout treatment groups. The rate of rejection, time to rejection onset, and survival (GS/PS) were not different among the groups. Fungal infections were fewer in patients treated with KETO (12%) than in controls (16%) and patients randomized to DILT (19%). KETO failed to prevent Aspergillus infection in one individual. The investigation failed to identify any harmful result of treating renal allograft recipients with either DILT or KETO for the purpose of reducing CsA expense.
authors.affiliation: Department of Surgery, University of Florida College, of Medicine, Gainesville.
authors.forename: P R
authors.initials: PR
authors.lastname: Patton
authors.forename: M E
authors.initials: ME
authors.lastname: Brunson
authors.forename: W W
authors.initials: WW
authors.lastname: Pfaff
authors.forename: R J
authors.initials: RJ
authors.lastname: Howard
authors.forename: J C
authors.initials: JC
authors.lastname: Peterson
authors.forename: E L
authors.initials: EL
authors.lastname: Ramos
authors.forename: J L
authors.initials: JL
authors.lastname: Karlix
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003365:Costs and Cost Analysis; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage* / Q000191:economics; D004110:Diltiazem / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D016572:Cyclosporine; D003404:Creatinine; D004110:Diltiazem; D007654:Ketoconazole